The discrepancy between the anticancer and the tumor-promoting effects of PPAR-γ agonists shown in the different studies reflects, as seen in vitro, the complexity of signaling interactions involved in tumor formation in vivo. The gene discussed is PPARG; the disease is neoplasm.